The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …

Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …

Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …

Chronic antigen stimulation during viral infections and cancer can lead to T cell exhaustion,
which is characterized by reduced effector function and proliferation, and the expression of …

T cell exhaustion limits antitumor immunity, but the molecular determinants of this process
remain poorly understood. Using a chronic stimulation assay, we performed genome-wide …

Abstract Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized
cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition …

Chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment with
enormous potential, demonstrating impressive antitumor activity in the treatment of …